The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | The evolution of the treatment landscape of ITP: entering the targeted era
In this video, Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses the evolving treatment landscape of immune thrombocytopenia (ITP), noting that the disease is entering a targeted therapy era, in which novel therapies aim to address specific aspects of the disease pathophysiology. Dr Al-Samkari highlights the significant impact of thrombopoietin (TPO) receptor agonists, which have revolutionized ITP treatment, as well as the development of promising novel therapies. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
ITP is a disease that has been evolving in sort of eras. And when we first had the initial era of what I call steroids, splenectomy, and salvage therapy, which, you know, dominated prior to the introduction of the thrombopoietin receptor agonists, and that was the second era in treatments. And now we’re really entering the targeted therapy era in ITP. Of course, thrombopoietin receptor agonists have revolutionized the way we treat ITP and remain a mainstay of therapy...
ITP is a disease that has been evolving in sort of eras. And when we first had the initial era of what I call steroids, splenectomy, and salvage therapy, which, you know, dominated prior to the introduction of the thrombopoietin receptor agonists, and that was the second era in treatments. And now we’re really entering the targeted therapy era in ITP. Of course, thrombopoietin receptor agonists have revolutionized the way we treat ITP and remain a mainstay of therapy. But the prospect of using medications that target specific aspects of the disease pathophysiology is really quite promising. And that’s where we are now. So there are a number of agents that are in development, both in early and late stage development at this point, that each take advantage of our enhanced and really more significant understanding of how this disease is more than just a disease of platelet autoantibodies. It’s a disease that affects multiple aspects of both cell-mediated and humoral immunity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Amgen, Alnylam, Alpine, Agios, Takeda, Pharmacosmos, Sanofi, Sobi, Novartis; Research funding to institution: Amgen, Agios, Novartis, Sobi, Vaderis.
